Scarica l'app Stockscreener
1.62
1.25%
0.02
Dopo l'orario di chiusura:
1.70
0.08
+4.94%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.60
Aprire:
$1.62
Volume 24 ore:
292.96K
Relative Volume:
0.40
Capitalizzazione di mercato:
$106.05M
Reddito:
-
Utile/perdita netta:
$-30.04M
Rapporto P/E:
-0.9586
EPS:
-1.69
Flusso di cassa netto:
$-27.38M
1 W Prestazione:
+5.19%
1M Prestazione:
+0.62%
6M Prestazione:
-31.36%
1 anno Prestazione:
-1.22%
Intervallo 1D:
$1.585
$1.6708
Intervallo di 1 settimana:
$1.51
$1.6708
Portata 52W:
$1.08
$3.79
Regulus Therapeutics Inc Stock (RGLS) Company Profile
Nome
Regulus Therapeutics Inc
Settore
Industria
Telefono
858-202-6300
Indirizzo
4224 CAMPUS POINT COURT, SAN DIEGO, CA
Regulus Therapeutics Inc Stock (RGLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-02 | Iniziato | Oppenheimer | Outperform |
| 2024-03-18 | Iniziato | Leerink Partners | Outperform |
| 2018-03-28 | Iniziato | B. Riley FBR, Inc. | Neutral |
| 2018-01-05 | Iniziato | Leerink Partners | Outperform |
| 2017-06-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-06 | Reiterato | Wedbush | Outperform |
| 2017-01-30 | Downgrade | Needham | Buy → Hold |
| 2017-01-30 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2016-12-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-11-02 | Reiterato | Needham | Buy |
| 2016-07-25 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | FBR Capital | Outperform |
| 2016-06-28 | Reiterato | Needham | Buy |
| 2016-06-07 | Reiterato | Chardan Capital Markets | Buy |
| 2016-04-13 | Iniziato | Chardan Capital Markets | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2015-04-21 | Ripresa | FBR Capital | Outperform |
| 2014-11-24 | Iniziato | Deutsche Bank | Buy |
| 2014-08-07 | Reiterato | FBR Capital | Outperform |
| 2013-08-14 | Reiterato | Needham | Buy |
Mostra tutto
Regulus Therapeutics Inc Borsa (RGLS) Ultime notizie
StockNews.com Upgrades Regulus Therapeutics (NASDAQ:RGLS) to "Sell" - MarketBeat
Oppenheimer’s latest rating for RGLS stock - Knox Daily
RGLS stock rated an Outperform by Oppenheimer - Knox Daily
Gaining Ground: Regulus Therapeutics Inc (RGLS) Closes Lower at 1.46, Down -6.41 - The Dwinnex
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Regulus Therapeutics (NASDAQ:RGLS) Raised to Sell at StockNews.com - MarketBeat
Regulus Therapeutics Inc [RGLS] Director makes an insider purchase of 4,000 shares worth 7280.0. - Knox Daily
Regulus Therapeutics Inc (RGLS) rating initates by Oppenheimer - Knox Daily
How does Regulus Therapeutics Inc (RGLS) change from a tortoise to a hare? - SETE News
Regulus Therapeutics Inc (RGLS) stock analysis: A comprehensive overview - US Post News
Regulus Therapeutics Inc (RGLS)’s stock chart: A technical perspective - US Post News
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - StockTitan
The Attractiveness of Investing In Regulus Therapeutics Inc (RGLS) is Growing - Knox Daily
Market Recap: Regulus Therapeutics Inc (RGLS)’s Positive Momentum, Closing at 1.59 - The Dwinnex
A Guide To The Risks Of Investing In Regulus Therapeutics Inc (RGLS) - Knox Daily
Vanguard Group Inc. Has $2.13 Million Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Regulus Therapeutics Reports Second Quarter 2024 Financial Resul - GuruFocus.com
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Longview News-Journal
Oppenheimer Reiterates “Outperform” Rating for Regulus Therapeutics (NASDAQ:RGLS) - Defense World
Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences - Longview News-Journal
Oppenheimer Reiterates Outperform Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
Analyzing Regulus Therapeutics Inc (RGLS) After Recent Trading Activity - Knox Daily
Regulus Therapeutics Inc. Forecasted to Earn Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Earns Buy Rating from HC Wainwright - Defense World
Regulus Therapeutics Inc. Forecasted to Post Q2 2025 Earnings of ($0.20) Per Share (NASDAQ:RGLS) - MarketBeat
HC Wainwright Reiterates "Buy" Rating for Regulus Therapeutics (NASDAQ:RGLS) - MarketBeat
RGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q2 2024 - InvestorPlace
Regulus: Q2 Earnings Snapshot - San Antonio Express-News
Regulus: Q2 Earnings Snapshot - San Francisco Chronicle
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - Nasdaq
Regulus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Updates - PR Newswire
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - StockTitan
Regulus Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - PR Newswire
Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at Oppenheimer - Defense World
Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at Oppenheimer - MarketBeat
RGLS stock rated an Outperform by Leerink Partners - Knox Daily
Regulus Therapeutics Inc (RGLS) did well last session? - US Post News
Regulus Therapeutics director buys $7.3k in company stock - Investing.com India
Regulus Therapeutics director buys $7.3k in company stock By Investing.com - Investing.com Canada
Regulus Therapeutics director buys $7.3k in company stock - Investing.com
A new trading data show Regulus Therapeutics Inc (RGLS) is showing positive returns. - SETE News
Regulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short Interest - MarketBeat
Regulus Therapeutics Inc (RGLS) presents a great opportunity, but the stock is slightly overvalued - US Post News
Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Target Price at $11.75 - MarketBeat
Regulus Therapeutics (NASDAQ:RGLS) Given “Buy” Rating at HC Wainwright - Defense World
Regulus Therapeutics' (RGLS) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Regulus Therapeutics’ (RGLS) “Buy” Rating Reiterated at HC Wainwright - American Banking and Market News
CVI Holdings LLC Invests $4.05 Million in Regulus Therapeutics Inc. (NASDAQ:RGLS) - MarketBeat
Short Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Grows By 48.0% - MarketBeat
Regulus Therapeutics Inc Azioni (RGLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
1.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):